• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Liver Cancer UK HomepageLiver Cancer UK

Part of the British Liver Trust

  • About us
  • Health professionals
  • Talk to a nurse 0800 652 7330
  • Twitter
  • Liver cancer information
    • Types of liver cancer
      • HCC liver cancer
        • Overview
        • What is HCC?
        • Symptoms
        • Risks and causes
        • Diagnosis
          • Tests
          • Questions for your doctor
        • Treatment
          • Stages
          • Early stage HCC (0-A)
          • Intermediate HCC (stage B)
          • Advanced HCC (stage C)
          • Very advanced (stage D)
          • If your HCC comes back (recurrence)
          • Check-ups
          • Outcomes (prognosis)
        • Living with HCC
      • Bile duct cancer
        • Overview
        • What is bile duct cancer?
        • Symptoms
        • Risks and causes
        • Diagnosis
          • Tests
          • Questions for your doctor
        • Treatment
          • Stages
          • If cancer can be removed
          • If cancer can’t be removed
          • If cancer is advanced or has come back
          • Questions for your doctor
          • Check-ups
          • Outcomes (prognosis)
        • Living with bile duct cancer
      • Rare types of liver cancers
      • Secondary liver cancer
    • Just diagnosed?
    • Types of treatment
      • Surgery
        • Types of surgery
        • Preparing for surgery
        • After surgery
      • Targeted cancer medicines (biological therapies)
      • Chemotherapy
      • Embolization, TACE and TARE or SIRT
      • Ablation
      • Radiotherapy
      • Treatment for symptoms and advanced cancer
      • About clinical trials
    • Risk and causes of liver cancer
    • Liver cancer tests
    • Living with liver cancer
      • Diet and exercise
      • Coping with advanced cancer
      • Mental wellbeing
      • Money matters
      • Support from others
      • Complementary and alternative therapies
      • Patient stories
    • Our booklets and resources
    • Glossary / useful words
  • Support for you
  • How you can help
  • News and blogs
  • Donate
Home » News and Blogs » British Liver Trust contributes to new report…
News

British Liver Trust contributes to new report launched by APPG on Minimally Invasive Cancer Therapies

July 4, 2022

The Trust attended the meeting of the All Party Parliamentary Group on Minimally Invasive Cancer Therapies today to represent patients with liver cancer. Members of Parliament, clinicians and other patient groups discussed how the recommendations in the newly launched report titled ‘Barriers to Patient Access of Minimally Invasive Cancer Therapies’ could be implicated. Link to report: Barriers to Patient Access of Minimally Invasive Cancer Therapies.

One of the therapies the report is seeking to address is selective internal radiation therapy (SIRT) which was approved by NICE for patients with hepatocellular carcinoma in 2021.

Vanessa Hebditch, our Director of Policy and Communications, had previously given evidence to the APPG enquiry on behalf of liver cancer patients. Martyn, one of our supporters, who was diagnosed with liver cancer in 2014 and was treated with selective internal radiation therapy (SIRT) also kindly assisted the APPG  by telling his story.

The report has three key recommendations :

1 Enable patient choice by improving awareness of new and emerging treatments for cancer:

  • The NHS website should include information on all available cancer interventions, referencing NICE recommendations where appropriate. All patients should be routinely informed to enable them to make an informed choice about their care if they wish.
  • The NHS should ensure that interventional radiology/oncology representation is present at every relevant organ specific multidisciplinary team e.g. Liver, Kidney, Prostate to ensure appropriate expertise allowing patient choice.

2 Ensure appropriate processes and infrastructure:

  • The Government should prioritise a strategic workforce plan for radiologists and interventional radiologists. This should ensure the NHS has sufficient numbers of trained interventional radiologists to deliver interventional oncology therapies including Selective Internal Radiational Therapy (SIRT), High Intensity Focused Ultrasound (HIFU) and Ablation in more centres.
  • Build on the existing infrastructure created by the 21 Cancer Alliances to ensure that minimally invasive cancer therapies are offered across the country.
  • NHS England must ensure new centres have the resources to introduce new services when recommended by NICE, ensuring an equitable and timely service throughout the country and reducing the need for very sick patients to travel long distances.

3 Ensure sufficient funding for approved cancer therapies:

  • Ensure that the full benefits of current investment into diagnostic and imaging technology are realised, by making similar investments into MICT that utilise these imaging technologies. An increase in access to diagnosis via imaging alone, without a corresponding increase in access to therapies, will not improve cancer outcomes.
  • Provide a simple pathway to funding, to ensure swift access for patients.
  • Ensure that Integrated Care Systems (ICSs) are held to account, adhering to national guidance and ensuring patient access to treatments.

Vanessa Hebditch,  told parliamentarians that clinicians in some areas of the country are not aware of the new therapies that are available for patients. This is because no hospital in their local area is offering selective internal therapy and they are not aware of referral pathways to specialist centres.

She said, “NICE approved this technology but we are still hearing 18 months on that patients cannot access this treatment. Patients are forced to travel long distances, in poor health, to access it as there are too few specialist interventional oncology centres. We need national leadership to promote equity of access so that selective internal radiation therapy is available to every patient who would benefit from it.”

Selective internal radiation therapy (SIRT) is a way of giving radiotherapy treatment for cancer in the liver that can’t be removed with surgery. It’s a type of internal radiotherapy, and is sometimes called radioembolisation. You can read more about access to SIRT here.

More news items
« One Cancer Voice calls on Sajid Javid to ensure the 10-Year Cancer Plan delivers the best cancer care system in Europe
MPs call for action to “level up” inequalities in liver disease care and outcomes across UK »

Footer

Liver Cancer UK logo
British Liver Trust logo

Quick links


  • Just been diagnosed
  • Living with cancer
  • Hepatocellular carcinoma (HCC)
  • Bile duct cancer

Contact us


Talk to a nurse on our helpline

0800 652 7330

General enquiries:

info@britishlivertrust.org.uk

01425 481 320

© British Liver Trust. All rights reserved. Registered Office: Venta Court, 20 Jewry Street, Winchester, SO23 8FE.
Registered Charity England and Wales 298858, Scotland SC042140. Company Limited by Guarantee Registered in England and Wales, Company No 2227706

Privacy policy | Cookies

Talk to a nurse on our helpline

0800 652 7330

Scroll Up